DOCSLIB.ORG

Detection of Causative Agents in Focus in Erysipelas Patients By

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Detection of Causative Agents in Focus in Erysipelas Patients By Detection of causative agents out using the ATB Expression ( «BioMerieux») Conclusion. The primary role of the β-HSA DNA contamination of hearth of erysipelas is and test systems ID32E, ID32Staph, ID32Strep, is indisputable, in the cases with complications depends on the presence of live staphylococci in focus in erysipelas patients ID32GN, identification of β-HS in groups A, B, C, mixt-infection can take a part in the etiology of on skin surface by bacteriological method and D, F and G (at Lancefield) - a latex agglutination the disease. PCR-RT with fluorescent Staphylococci on skin: PCR reaction(Pastorex Strep Kits; «Bio-Rad»,France) hybridization detection showed the highly informative content in the study of the blood and S.aureus No staphyl. S.epid./saprop. Volchkova E.V.1, Belaia O.F.1, Troickii V.I.1, The overall frequency of detection of different Svistunova Т.S.2,Potekaeva S.N.2, microorganisms (85%) in PCR in patients bulls punctuate. and it was more informative in Staphylococcus DNA in hearth: Domonova E.A.3 with erysipelas (n=60) identifying the microflora in patients with 1 erysipelas than bacteriological method. The 80% 32% # 7,0% # Sechenov First Moscow State Medical Staphylococci S.aureus-39% University, 2 Infectious Clinical Hospital №2, bacteriological method showed low efficacy in 74.5% MSSA:MRSA = 9:2 PCR results: 3Central Research Institute of Epidemiology, detecting of Str.pyogenes, however, positive S.epidermidis and/or Moscow, Russian Federation results of bacteriological research can serve as MRSA -2 - - S.saprophyticus-43% MRCoNS - 4 - MRCoNS -5 Erysipelas is a common infection of the skin an objective criterion of therapy correction based MRCoNS-20% MSSA - 7 MSSA -1 MSSA - 2 surface layer, unlike cellulitis and necrotizing on identified microbes. fasciitis, which also affect the subcutaneous Streptococci S.pyogenes - 33,3% Clinical and laboratory parameters in detection «Load” of Staphylococcus DNA per patient: tissue. The main causative agent is widely 47,06% Others – 4% of Staphylococcus (%) at erysipelas 1,1 0,4 # 0,07 # recognized as β-hemolytic streptococcus group Symptom Subgr.1 Subgr.2 Subgr.3 Others K.pneumoniae - 3 A (β-HSA) and G, but recently on discussed the Bacter. PCR+ no staphy- «Load” of all microbe DNA per patient: microbes P.aeruginosa - 3 participation of Staphylococcus aureus and method+ Lococci 22% 1,4 0,8 0,3 # A.baumanii - 2 Fever: 39,00,1 38,70,1 38, 90,2 gram-negative bacteria in the development of 0 erysipelas. Pathogen cultures isolation by C.normanensis - 1 max( С) # # - differences to subgr.1 (р≤0,05) bacteriological method in patients with C.musifaciens - 1 duration 9,20,6 8,10,9 9,61,5 (day) References: erysipelas is a difficult task, so in most cases of Proteus - 1 Erythema: 1,50,1 1,90,2 1,80,3 1.Ray G. T., Suaya J. A. and Baxter R. Inciden- erysipelas diagnosis is established by clinical Results. The bacteriological study demonst- onset(day) # ce, microbiology, and patient characteristics of and epidemiologic data. rated a wide range of the pathogens, preferen- duration 7,9 0,4 8,30,8 7,70,6 skin and soft-tissue infections in a U.S. popula- Objective: to study the etiological structure tially staphylococcus (S.epidermidis 22,2%, (day) tion: a retrospective population-based study. of the disease in patients with erysipelas of the S.aureus 22,2%, S.saprophyticus 11,1%, S.pyo- # - differences to subgr. 2 (p ≤ 0,05) BMC Infectious Diseases. 2013; 13:252-26. lower extremities by using bacteriological 2.Gunderson C.G., Martinello R.A. A systematic genes 2 patients, Str.dysgalacticeae equisimilis . method and PCR. Residual effects in the detection of staphylococci review of bacteremias in cellulitis & erysipelas. 1), mainly- in skin smears, while the informa- by bacteriological method and PCR Materials/methods. A total of 60 in-patients Journal of Infection. 2012; 64:148-155 tiveness of blood culture and bulls punctate was Subgr.1 Subgr.2 Subgr.3 with erysipelas of the lower limbs, mainly with Symptom 3.Larru B., Gerber J.S. Cutaneous bacterial low. Monoinfection - 48%, mixt-infection-10%. In Bacter.+ PCR + No staph. bullous hemorrhagic form, were examined. The Infections caused by Staphylococcus aureus PCR it was confirmed a leading role of β-HSA in Congestive 25,0% 28,6% and Streptococcus pyogenes in Infants and average age of patients was 53,6±1,7 years. 66,7% the development of bullous-hemorrhagic erysi- hyperemia # # children. Pediatr Clin N Am 61. 2014:457–478 We examined blood, smears from the skin in the pelas (61% in bull puncture), and in smears from 4.Troitskiy V.I., Erovichenkov A.A., Potekaeva area of the hearth and bulls punctate by using Prolonged the hearth surface -S.aureus (MSSA-6%, reparation, S.A., Svistunova T.S., Belaya O.F., Volchkova bacteriological method and PCR with fluorescent 25,9% 43,8% 7,1% MRSA-2%), MRCoNS (6%), but some other trophic E.V. Diversity of detected pathogens from pati- hybridization detection in real time. Identification microbes - only in combination with ulcers ents with erysipelas. Epidemiology and Infec- of isolated pure cultures to species was carried tious Diseases. 2015; 20 (2):34-7 [In Russian] Streptococcus and/or Staphylococcus. #- differences to subgr.1 (p ≤ 0,05) VasiliyTroitsky: [email protected] .
Load more

Recommended publications
  • Naeglaria and Brain Infections
    Can bacteria shrink tumors? Cancer Therapy: The Microbial Approach n this age of advanced injected live Streptococcus medical science and into cancer patients but after I technology, we still the recipients unfortunately continue to hunt for died from subsequent innovative cancer therapies infections, Coley decided to that prove effective and safe. use heat killed bacteria. He Treatments that successfully made a mixture of two heat- eradicate tumors while at the killed bacterial species, By Alan Barajas same time cause as little Streptococcus pyogenes and damage as possible to normal Serratia marcescens. This Alani Barajas is a Research and tissue are the ultimate goal, concoction was termed Development Technician at Hardy but are also not easy to find. “Coley’s toxins.” Bacteria Diagnostics. She earned her bachelor's degree in Microbiology at were either injected into Cal Poly, San Luis Obispo. The use of microorganisms in tumors or into the cancer therapy is not a new bloodstream. During her studies at Cal Poly, much idea but it is currently a of her time was spent as part of the undergraduate research team for the buzzing topic in cancer Cal Poly Dairy Products Technology therapy research. Center studying spore-forming bacteria in dairy products. In the late 1800s, German Currently she is working on new physicians W. Busch and F. chromogenic media formulations for Fehleisen both individually Hardy Diagnostics, both in the observed that certain cancers prepared and powdered forms. began to regress when patients acquired accidental erysipelas (cellulitis) caused by Streptococcus pyogenes. William Coley was the first to use New York surgeon William bacterial injections to treat cancer www.HardyDiagnostics.com patients.
    [Show full text]
  • Drug-Resistant Streptococcus Pneumoniae and Methicillin
    NEWS & NOTES Conference Summary pneumoniae can vary among popula- conference sessions was that statically tions and is influenced by local pre- sound methods of data collection that Drug-resistant scribing practices and the prevalence capture valid, meaningful, and useful of resistant clones. Conference pre- data and meet the financial restric- Streptococcus senters discussed the role of surveil- tions of state budgets are indicated. pneumoniae and lance in raising awareness of the Active, population-based surveil- Methicillin- resistance problem and in monitoring lance for collecting relevant isolates is the effectiveness of prevention and considered the standard criterion. resistant control programs. National- and state- Unfortunately, this type of surveil- Staphylococcus level epidemiologists discussed the lance is labor-intensive and costly, aureus benefits of including state-level sur- making it an impractical choice for 1 veillance data with appropriate antibi- many states. The challenges of isolate Surveillance otic use programs designed to address collection, packaging and transport, The Centers for Disease Control the antibiotic prescribing practices of data collection, and analysis may and Prevention (CDC) convened a clinicians. The potential for local sur- place an unacceptable workload on conference on March 12–13, 2003, in veillance to provide information on laboratory and epidemiology person- Atlanta, Georgia, to discuss improv- the impact of a new pneumococcal nel. ing state-based surveillance of drug- vaccine for children was also exam- Epidemiologists from several state resistant Streptococcus pneumoniae ined; the vaccine has been shown to health departments that have elected (DRSP) and methicillin-resistant reduce infections caused by resistance to implement enhanced antimicrobial Staphylococcus aureus (MRSA).
    [Show full text]
  • Diagnostic Code Descriptions (ICD9)
    INFECTIONS AND PARASITIC DISEASES INTESTINAL AND INFECTIOUS DISEASES (001 – 009.3) 001 CHOLERA 001.0 DUE TO VIBRIO CHOLERAE 001.1 DUE TO VIBRIO CHOLERAE EL TOR 001.9 UNSPECIFIED 002 TYPHOID AND PARATYPHOID FEVERS 002.0 TYPHOID FEVER 002.1 PARATYPHOID FEVER 'A' 002.2 PARATYPHOID FEVER 'B' 002.3 PARATYPHOID FEVER 'C' 002.9 PARATYPHOID FEVER, UNSPECIFIED 003 OTHER SALMONELLA INFECTIONS 003.0 SALMONELLA GASTROENTERITIS 003.1 SALMONELLA SEPTICAEMIA 003.2 LOCALIZED SALMONELLA INFECTIONS 003.8 OTHER 003.9 UNSPECIFIED 004 SHIGELLOSIS 004.0 SHIGELLA DYSENTERIAE 004.1 SHIGELLA FLEXNERI 004.2 SHIGELLA BOYDII 004.3 SHIGELLA SONNEI 004.8 OTHER 004.9 UNSPECIFIED 005 OTHER FOOD POISONING (BACTERIAL) 005.0 STAPHYLOCOCCAL FOOD POISONING 005.1 BOTULISM 005.2 FOOD POISONING DUE TO CLOSTRIDIUM PERFRINGENS (CL.WELCHII) 005.3 FOOD POISONING DUE TO OTHER CLOSTRIDIA 005.4 FOOD POISONING DUE TO VIBRIO PARAHAEMOLYTICUS 005.8 OTHER BACTERIAL FOOD POISONING 005.9 FOOD POISONING, UNSPECIFIED 006 AMOEBIASIS 006.0 ACUTE AMOEBIC DYSENTERY WITHOUT MENTION OF ABSCESS 006.1 CHRONIC INTESTINAL AMOEBIASIS WITHOUT MENTION OF ABSCESS 006.2 AMOEBIC NONDYSENTERIC COLITIS 006.3 AMOEBIC LIVER ABSCESS 006.4 AMOEBIC LUNG ABSCESS 006.5 AMOEBIC BRAIN ABSCESS 006.6 AMOEBIC SKIN ULCERATION 006.8 AMOEBIC INFECTION OF OTHER SITES 006.9 AMOEBIASIS, UNSPECIFIED 007 OTHER PROTOZOAL INTESTINAL DISEASES 007.0 BALANTIDIASIS 007.1 GIARDIASIS 007.2 COCCIDIOSIS 007.3 INTESTINAL TRICHOMONIASIS 007.8 OTHER PROTOZOAL INTESTINAL DISEASES 007.9 UNSPECIFIED 008 INTESTINAL INFECTIONS DUE TO OTHER ORGANISMS
    [Show full text]
  • WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/05 (2006.01) A61P 31/02 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/CA20 14/000 174 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 4 March 2014 (04.03.2014) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 13/790,91 1 8 March 2013 (08.03.2013) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: LABORATOIRE M2 [CA/CA]; 4005-A, rue kind of regional protection available): ARIPO (BW, GH, de la Garlock, Sherbrooke, Quebec J1L 1W9 (CA). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: LEMIRE, Gaetan; 6505, rue de la fougere, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Sherbrooke, Quebec JIN 3W3 (CA).
    [Show full text]
  • Skin and Soft Tissue Infections Ohsuerin Bonura, MD, MCR Oregon Health & Science University Objectives
    Difficult Skin and Soft tissue Infections OHSUErin Bonura, MD, MCR Oregon Health & Science University Objectives • Compare and contrast the epidemiology and clinical presentation of common skin and soft tissue diseases • State the management for skin and soft tissue infections OHSU• Differentiate true infection from infectious disease mimics of the skin Casey Casey is a 2 year old boy who presents with this rash. What is the best treatment? A. Soap and Water B. Ibuprofen, it will self OHSUresolve C. Dicloxacillin D. Mupirocin OHSUImpetigo Impetigo Epidemiology and Treatment OHSU Ellen Ellen is a 54 year old morbidly obese woman with DM, HTN and venous stasis who presented with a painful left leg and fever. She has had 3 episodes in the last 6 months. What do you recommend? A. Cefazolin followed by oral amoxicillin prophylaxis B. Vancomycin – this is likely OHSUMRSA C. Amoxicillin – this is likely erysipelas D. Clindamycin to cover staph and strep cellulitis Impetigo OHSUErysipelas Erysipelas Risk: lymphedema, stasis, obesity, paresis, DM, ETOH OHSURecurrence rate: 30% in 3 yrs Treatment: Penicillin Impetigo Erysipelas OHSUCellulitis Cellulitis • DEEPER than erysipelas • Microbiology: – 6-48hrs post op: think GAS… too early for staph (days in the making)! – Periorbital – Staph, Strep pneumoniae, GAS OHSU– Post Varicella - GAS – Skin popping – Staph + almost anything! Framework for Skin and Soft Tissue Infections (SSTIs) NONPurulent Purulent Necrotizing/Cellulitis/Erysipelas Furuncle/Carbuncle/Abscess Severe Moderate Mild Severe Moderate Mild I&D I&D I&D I&D IV Rx Oral Rx C&S C&S C&S C&S Vanc + Pip-tazo OHSUEmpiric IV Empiric MRSA Oral MRSA TMP/SMX Doxy What Are Your “Go-To” Oral Options For Non-Purulent SSTI? Amoxicillin Doxycycline OHSUCephalexin Doxycycline Trimethoprim-Sulfamethoxazole OHSU Miller LG, et al.
    [Show full text]
  • Methicillin-Resistant Staphylococcus Aureus and Clostridium Difficile Infection Lab ID Event Report
    Methicillin-Resistant Staphylococcus aureus and Clostridium difficile Infection Lab ID Event Report Facility Name: Date of Event Report: Sex: M F □ □ Date of Birth: Race: □ White □ Black or African American □ Asian □ Native Hawaiian or Other Pacific Islander □ American Indian or Alaska Native □ Other [specify] __________________ Ethnicity: □ Hispanic or Latino □ Not Hispanic or Latino □ Other Event Details Date Specimen Collected: Date Specimen Finalized: Specific Organism Type: (Check one) □ Methicillin-Resistant Staphylococcus aureus (MRSA) □ Clostridium difficile Infection (CDI) Specimen Source (e.g. blood, wound, sputum, bone, Specimen Body Site/System try to be as specific as possible urine, stool): (e.g. upper right arm, foot ulcer, gastrointestinal tract): Date Admitted to your Facility: Location at time of Specimen Collection (name of specific unit, ward, or floor): Date Admitted to Location: Has patient been discharged from your facility in the past 3 months? Yes No If Yes, date of last discharge from your facility: Comments Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)). For use by Michigan Department of Community Health (MDCH), Surveillance for Healthcare-Associated and Resistant Pathogens (SHARP) Unit’s MRSA/CDI Prevention Initiative (Coordinator: Gail Denkins, SHARP Intern: Kate Manton); fax completed forms to (517) 335-8263, ATTN: Kate Manton.
    [Show full text]
  • Early History of Infectious Disease 
    © Jones and Bartlett Publishers. NOT FOR SALE OR DISTRIBUTION CHAPTER ONE EARLY HISTORY OF INFECTIOUS 1 DISEASE Kenrad E. Nelson, Carolyn F. Williams Epidemics of infectious diseases have been documented throughout history. In ancient Greece and Egypt accounts describe epidemics of smallpox, leprosy, tuberculosis, meningococcal infections, and diphtheria.1 The morbidity and mortality of infectious diseases profoundly shaped politics, commerce, and culture. In epidemics, none were spared. Smallpox likely disfigured and killed Ramses V in 1157 BCE, although his mummy has a significant head wound as well.2 At times political upheavals exasperated the spread of disease. The Spartan wars caused massive dislocation of Greeks into Athens triggering the Athens epidemic of 430–427 BCE that killed up to one half of the population of ancient Athens.3 Thucydides’ vivid descriptions of this epidemic make clear its political and cultural impact, as well as the clinical details of the epidemic.4 Several modern epidemiologists have hypothesized on the causative agent. Langmuir et al.,5 favor a combined influenza and toxin-producing staphylococcus epidemic, while Morrens and Chu suggest Rift Valley Fever.6 A third researcher, Holladay believes the agent no longer exists.7 From the earliest times, man has sought to understand the natural forces and risk factors affecting the patterns of illness and death in society. These theories have evolved as our understanding of the natural world has advanced, sometimes slowly, sometimes, when there are profound break- throughs, with incredible speed. Remarkably, advances in knowledge and changes in theory have not always proceeded in synchrony. Although wrong theories or knowledge have hindered advances in understanding, there are also examples of great creativity when scientists have successfully pursued their theories beyond the knowledge of the time.
    [Show full text]
  • Association Between Carriage of Streptococcus Pneumoniae and Staphylococcus Aureus in Children
    BRIEF REPORT Association Between Carriage of Streptococcus pneumoniae and Staphylococcus aureus in Children Gili Regev-Yochay, MD Context Widespread pneumococcal conjugate vaccination may bring about epidemio- Ron Dagan, MD logic changes in upper respiratory tract flora of children. Of particular significance may Meir Raz, MD be an interaction between Streptococcus pneumoniae and Staphylococcus aureus, in view of the recent emergence of community-acquired methicillin-resistant S aureus. Yehuda Carmeli, MD, MPH Objective To examine the prevalence and risk factors of carriage of S pneumoniae Bracha Shainberg, PhD and S aureus in the prevaccination era in young children. Estela Derazne, MSc Design, Setting, and Patients Cross-sectional surveillance study of nasopharyn- geal carriage of S pneumoniae and nasal carriage of S aureus by 790 children aged 40 Galia Rahav, MD months or younger seen at primary care clinics in central Israel during February 2002. Ethan Rubinstein, MD Main Outcome Measures Carriage rates of S pneumoniae (by serotype) and S aureus; risk factors associated with carriage of each pathogen. TREPTOCOCCUS PNEUMONIAE AND Results Among 790 children screened, 43% carried S pneumoniae and 10% car- Staphylococcus aureus are com- ried S aureus. Staphylococcus aureus carriage among S pneumoniae carriers was 6.5% mon inhabitants of the upper vs 12.9% in S pneumoniae noncarriers. Streptococcus pneumoniae carriage among respiratory tract in children and S aureus carriers was 27.5% vs 44.8% in S aureus noncarriers. Only 2.8% carried both Sare responsible for common infec- pathogens concomitantly vs 4.3% expected dual carriage (P=.03). Risk factors for tions. Carriage of S aureus and S pneu- S pneumoniae carriage (attending day care, having young siblings, and age older than moniae can result in bacterial spread and 3 months) were negatively associated with S aureus carriage.
    [Show full text]
  • Clostridium Difficile Infection: How to Deal with the Problem DH INFORMATION RE ADER B OX
    Clostridium difficile infection: How to deal with the problem DH INFORMATION RE ADER B OX Policy Estates HR / Workforce Commissioning Management IM & T Planning / Finance Clinical Social Care / Partnership Working Document Purpose Best Practice Guidance Gateway Reference 9833 Title Clostridium difficile infection: How to deal with the problem Author DH and HPA Publication Date December 2008 Target Audience PCT CEs, NHS Trust CEs, SHA CEs, Care Trust CEs, Medical Directors, Directors of PH, Directors of Nursing, PCT PEC Chairs, NHS Trust Board Chairs, Special HA CEs, Directors of Infection Prevention and Control, Infection Control Teams, Health Protection Units, Chief Pharmacists Circulation List Description This guidance outlines newer evidence and approaches to delivering good infection control and environmental hygiene. It updates the 1994 guidance and takes into account a national framework for clinical governance which did not exist in 1994. Cross Ref N/A Superseded Docs Clostridium difficile Infection Prevention and Management (1994) Action Required CEs to consider with DIPCs and other colleagues Timing N/A Contact Details Healthcare Associated Infection and Antimicrobial Resistance Department of Health Room 528, Wellington House 133-155 Waterloo Road London SE1 8UG For Recipient's Use Front cover image: Clostridium difficile attached to intestinal cells. Reproduced courtesy of Dr Jan Hobot, Cardiff University School of Medicine. Clostridium difficile infection: How to deal with the problem Contents Foreword 1 Scope and purpose 2 Introduction 3 Why did CDI increase? 4 Approach to compiling the guidance 6 What is new in this guidance? 7 Core Guidance Key recommendations 9 Grading of recommendations 11 Summary of healthcare recommendations 12 1.
    [Show full text]
  • Listeriosis (“Circling Disease”) Extended Version
    Zuku Review FlashNotesTM Listeriosis (“circling disease”) Extended Version Classic case: Silage-fed adult cow, head tilt, circling, asymmetric sensation loss on face Presentation: Signalment and History Adult cattle, sheep, goats, (possibly camelids) . Indoors in winter with feeding of silage . Extremely rare in horses Poultry and pet birds Human listeria outbreaks Clinical signs (mammals) Head tilt Circling Dullness Sensory and motor dysfunction of trigeminal nerve . Asymmetric sensory loss on face . Weak jaw closure Purulent ophthalmitis Exposure keratitis Isolation from rest of herd Ocular and nasal discharge Listeriosis in a Holstein. Food remaining in mouth Note the head tilt and drooped ear Bloat Marked somnolence Tetraparesis, ataxia Poor to absent palpebral reflexes Difficulty swallowing/poor gag reflex Tongue paresis Obtundation, semicoma, death Clinical signs (avian listeriosis) Often subclinical Older birds and poultry (septicemia) . Depression, lethargy . Sudden death Younger birds and poultry (chronic form) . Torticollis . Paresis/paralysis DDX: Listeriosis in an ataxic goat Mammals Brainstem abscess, basilar empyema, otitis media/interna, Maedi-Visna, rabies, caprine arthritis-encephalitis, Parelaphostrongylus tenuis, scrapie Avian Colibacillosis, pasteurellosis, erysipelas, velogenic viscerotropic Newcastle disease 1 Zuku Review FlashNotesTM Listeriosis (“circling disease”) Extended Version Test(s) of choice: Mammals-Clinical signs and Cerebrospinal fluid (CSF) analysis . Mononuclear pleocytosis,
    [Show full text]
  • Methicillin-Resistant Staphylococcus Aureus (MRSA)
    Methicillin-Resistant Staphylococcus Aureus (MRSA) Over the past several decades, the incidence of resistant gram-positive organisms has risen in the United States. MRSA strains, first identified in the 1960s in England, were first observed in the U.S. in the mid 1980s.1 Resistance quickly developed, increasing from 2.4% in 1979 to 29% in 1991.2 The current prevalence for MRSA in hospitals and other facilities ranges from <10% to 65%. In 1999, MRSA accounted for more than 50% of all Staphylococcus aureus isolates within U.S. intensive care units.3, 4 The past years, however, outbreaks of MRSA have also been seen in the community setting, particularly among preschool-age children, some of whom have attended day-care centers.5, 6, 7 MRSA does not appear to be more virulent than methicillin-sensitive Staphylococcus aureus, but certainly poses a greater treatment challenge. MRSA also has been associated with higher hospital costs and mortality.8 Within a decade of its development, methicillin resistance to Staphylococcus aureus emerged.9 MRSA strains generally are now resistant to other antimicrobial classes including aminoglycosides, beta-lactams, carbapenems, cephalosporins, fluoroquinolones and macrolides.10,11 Most of the resistance was secondary to production of beta-lactamase enzymes or intrinsic resistance with alterations in penicillin-binding proteins. Staphylococcus aureus is the most frequent cause of nosocomial pneumonia and surgical- wound infections and the second most common cause of nosocomial bloodstream infections.12 Long-term care facilities (LTCFs) have developed rates of MRSA ranging from 25%-35%. MRSA rates may be higher in LTCFs if they are associated with hospitals that have higher rates.13 Transmission of MRSA generally occurs through direct or indirect contact with a reservoir.
    [Show full text]
  • Methicillin Resistant Staphylococcus Aureus (MRSA)
    Methicillin resistant Staphylococcus aureus (MRSA), Clostridium difficile and ESBL-producing Escherichia coli in the home and community: assessing the problem, controlling the spread An expert report commissioned by the International Scientific Forum on Home Hygiene © International Scientific Forum on Home Hygiene, 2006 2 CONTENTS ACKNOWLEDGMENTS 4 SUMMARY 5 1. INTRODUCTION – INFECTIOUS DISEASE AND HYGIENE IN THE 21ST CENTURY 7 2. THE CHAIN OF INFECTION TRANSMISSION IN THE HOME 10 3. METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) 11 3.1 CHARACTERISTICS OF STAPHYLOCOCCUS AUREUS AND METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS 11 3.2 HOSPITAL-ACQUIRED, HEALTHCARE ASSOCIATED AND COMMUNITY ACQUIRED MRSA 11 3.3 UNDERSTANDING THE CHAIN OF INFECTION FOR S. AUREUS AND MRSA IN THE HOME 13 3.4 WHAT ARE THE RISKS ASSOCIATED WITH S. AUREUS AND MRSA IN THE COMMUNITY? 22 4. CLOSTRIDIUM DIFFICILE 24 4.1 CHARACTERISTICS OF CLOSTRIDIUM DIFFICILE 24 4.2 HOSPITAL-ACQUIRED AND COMMUNITY- ACQUIRED C. DIFFICILE 24 4.3 UNDERSTANDING THE CHAIN OF INFECTION FOR C. DIFFICILE IN THE HOME 25 4.4 WHAT ARE THE RISKS ASSOCIATED WITH C. DIFFICILE IN THE HOME AND COMMUNITY 28 5. EXTENDED-SPECTRUM ß-LACTAMASE ESCHERICHIA COLI (ESBLS) 30 5.1 CHARACTERISTICS OF ESCHERICHIA COLI 30 5.2 HOSPITAL AND COMMUNITY-ACQUIRED ESBL-PRODUCING E. COLI INFECTIONS 31 5.3 UNDERSTANDING THE CHAIN OF INFECTION FOR E. COLI AND ESBL-PRODUCING E. COLI IN THE HOME 31 5.4 RISKS ASSOCIATED WITH ESBLS IN THE COMMUNITY 33 6. REDUCING THE RISKS OF TRANSMISSION OF METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA), CLOSTRIDIUM DIFFICILE AND ESBL-PRODUCING ESCHERICHIA COLI IN THE HOME AND COMMUNITY - DEVELOPING A RISK-BASED APPROACH TO HOME HYGIENE 35 6.1 BREAKING THE CHAIN OF TRANSMISSION OF INFECTION IN THE HOME 35 6.2 DEVELOPING A RISK-BASED APPROACH TO HOME HYGIENE 35 6.3 INTERRUPTING THE CHAIN OF INFECTION TRANSMISSION IN THE HOME 38 7.
    [Show full text]